¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"lymphocyte defined antigen"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
reticular lymphocyte
±×¹°¸²ÇÁ±¸, ¸Á»ó¸²ÇÁ±¸
sensitized lymphocyte
¹Î°¨È¸²ÇÁ±¸
antigen
Ç׿ø
antigen analysis
Ç׿øºÐ¼®
antigen binding capacity
Ç׿ø°áÇÕ´É
antigen binding fragment
Ç׿ø°áÇÕºÎÀ§
antigen binding receptor
Ç׿ø°áÇÕ¼ö¿ëü
antigen capture assay
Ç׿øÆ÷È¹ÃøÁ¤
antigen competition
Ç׿ø°æÀï
antigen diffusion constant
Ç׿øÈ®»ê»ó¼ö
antigen excess
Ç׿ø°úÀ×
antigen excess zone
Ç׿ø°úÀ×±¸¿ª
antigen mimicry
Ç׿øÀ¯»ç¼º
antigen modification
Ç׿øº¯È, Ç׿ø¼ö½Ä
antigen presentation
Ç׿øÁ¦½Ã
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
1
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
antigen-binding site
Ç׿ø°áÇÕºÎÀ§
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
short lived lymphocyte
´Ü»ý¸²ÇÁ±¸, ªÀº¼ö¸í¸²ÇÁ±¸
thymic lymphocyte
°¡½¿»ù¸²ÇÁ±¸
thymus-derived lymphocyte
°¡½¿»ùÀ¯·¡¸²ÇÁ±¸
mixed lymphocyte reaction
¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
mixed lymphocyte culture test
È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
monocyte lymphocyte ratio
´ÜÇÙ±¸¸²ÇÁ±¸ºñÀ²
primed lymphocyte typing
ÃÊȸÇ׿øÀÚ±ØÈĸ²ÇÁ±¸Çüº°È
primed lymphocyte-typing test
°¨ÀÛ¸²ÇÁ±¸Çüº°°Ë»ç
antigen
Ç׿ø
accessible antigen
Á¢±Ù°¡´ÉÇ׿ø
antigen competition
Ç׿ø°æÀï
antigen excess
Ç׿ø°úÀ×
antigen mimicry
Ç׿øÀ¯»ç¼º
antigen modification
Ç׿øº¯È, Ç׿ø¼ö½Ä
antigen presentation
Ç׿øÀü´Þ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
hodgkins disease,lymphocyte predominance
¸²ÇÁ±¸ ÇöÀúÇü
primed lymphocyte
ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
primed lymphocyte typing
ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È
primed lymphocyte-typing test
ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
ABH antigen
ABH Ç׿ø
B antigen
B Ç׿ø(ù÷ê«)
B cell antigen
B ¼¼Æ÷Ç׿ø
CA 19-9 antigen
CA 19-9 Ç׿ø
CA 50 antigen
CA 50 Ç׿ø
CA-2<
>
CA-2<<ÄÝ·ÎÀ̵åÇ׿ø>>
CD5 antigen
CD5 Ç׿ø
CEA(carcinoembryonic antigen)
žƼº¾ÏÇ׿ø
Cartwright antigen
īƮ¶óÀÌÆ®Ç׿ø
Cha antigen
Cha Ç׿ø
Chido (Ch") antigen
Chido(Ch") Ç׿ø
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
killer lymphocyte
»ìÇØ¸²ÇÁ±¸
large lymphocyte
´ë¸²ÇÁ±¸(¡Ï¹).
large lymphocyte
Å«¸²ÇÁ±¸
large lymphocyte
´ë¸²ÇÁ±¸(?Ë´).
leukocytoid lymphocyte
¹éÇ÷±¸¾ç ¸²ÇÁ±¸
lymphocyte
¸²ÇÁ±¸(¡Ï¹).
lymphocyte
¸²ÇÁ±¸
lymphocyte activating factor
¸²ÇÁ±¸È°¼ºÀÎÀÚ
lymphocyte activating factor (LAF)
¸²ÇÁ±¸ Ȱ¼ºÈÀÎÀÚ
lymphocyte analysis
¸²ÇÁ±¸ºÐ¼®
lymphocyte culture, mixed
È¥ÇÕ ¸²ÇÁ±¸¹è¾ç
lymphocyte development
¸²ÇÁ±¸¹ßÀ°
lymphocyte dysfunction
¸²ÇÁ±¸±â´ÉÀå¾Ö<--ºÎÀü>
lymphocyte inhibitory factor (LIF)
¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
lymphocyte interaction
¸²ÇÁ±¸»óÈ£ÀÛ¿ë.
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½